Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans. The rate of absorption of celexocib is moderate when given orally (peak plasma drug concentration occurs after 2 to 4 hours), although the extent of absorption is not known. Upper gastrointestinal complication rates in clinical trials are significantly lower for celecoxib than for traditional nonselective NSAIDs (e.g. The selective inhibition of COX- 2 is thought to lead to a reduction in the unwanted effects of NSAIDs. Preliminary data suggest that celecoxib also has analgesic and anticancer properties. Here, we demonstrate that celecoxib increases the sensitivity of bacteria to the antibiotics ampicillin, kanamycin, chloramphenicol, and ciprofloxacin by accumulating the drugs inside the cell, thus reversing MDR in bacteria.Ĭlinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase- 2 inhibitor.ĭavies, N M McLachlan, A J Day, R O Williams, K MĬelecoxib, a nonsteroidal anti-inflammatory drug (NSAID), is the first specific inhibitor of cyclo-oxygenase- 2 (COX- 2) approved to treat patients with rheumatism and osteoarthritis. ![]() Accumulating evidence suggests that the cyclooxygenase- 2 (COX- 2)-specific inhibitor celecoxib would not only inhibit COX- 2 but also help in the reversal of drug resistance in cancers by inhibiting the MDR1 efflux pump. Multidrug resistance (MDR) is a major problem in the treatment of infectious diseases and cancer. ![]() Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase- 2 inhibitor. In this article, we reviewed COX- 2 selectivity, the pharmacological properties of celecoxib, the use of celecoxib for cancer prevention and the mechanisms of chemoprevention. The effects of NSAIDs on tumor growth remain unclear, but are most likely to be multifocal. For this purpose, celecoxib is being used for different cancer types. Chemoprevention is the use of pharmacological or natural agents to prevent, suppress, interrupt or reverse the process of carcinogenesis. Celecoxib is a potent COX- 2 inhibitor being developed for the treatment of rheumatoid arthritis and osteoarthritis. Selective COX- 2 inhibitors provide potent anti-inflammatory and analgesic effects without the side effects of gastric and renal toxicity and inhibition of platelet function. These drugs act primarily by inhibiting cyclooxygenase enzyme, which has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase- 2 (COX- 2). They may also have a role in the management of cancer prevention, Alzheimer's disease and prophylaxis against cardiovascular disease. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutic agents in the treatment of pain, inflammation and fever. ![]() Kismet, Kemal Akay, M Turan Abbasoglu, Osman Ercan, Aygün Celecoxib: a potent cyclooxygenase- 2 inhibitor in cancer prevention.
0 Comments
Leave a Reply. |